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ABSTRACT
Objective Osteoporosis and fractures are frequently
encountered in patients with Crohn’s disease. In order to
prevent fractures, treatment with bone protecting drugs
appears warranted early in the course of bone disease
when bone loss is not yet prominent. We therefore
aimed to demonstrate a beneficial effect on bone density
of the bisphosphonate risedronate in osteopenic Crohn’s
disease patients.
Methods This double-blind, placebo-controlled
randomised trial of risedronate with calcium and vitamin
D supplementation was performed in osteopenic Crohn’s
disease patients. Patients were treated for 2 years with
follow-up after 3 and after every 6 months. Disease
characteristics and activity and bone turnover markers
were assessed at all visits; dual x-ray absorptiometry was
performed at baseline, 12 and 24 months; radiographs
of the spine at baseline and 24 months.
Results Of 132 consenting patients, 131 were
randomised (67 placebo and 64 risedronate). Patient
characteristics were similar in both groups, although the
risedronate group was slightly heavier (body mass index
24.3 vs 23.0 kg/m2). Bone mineral density at lumbar
spine increased 0.04 g/cm2 on average in the risedronate
group versus 0.01 g/cm2 in the placebo group
(p=0.007). The mean increase in total hip bone mineral
density was 0.03 versus 0.01 g/cm2, respectively
(p=0.071). Fracture prevalence and incidence were
similar. Change of T-scores and concentrations of bone
turnover markers were consistent with a beneficial effect
of risedronate when compared with placebo. The effect
of risedronate was primarily demonstrated in the first
12 months of treatment. No serious unexpected
suspected adverse events were observed.
Conclusions A 24-month treatment course with
risedronate 35 mg once weekly, concomitant with
calcium and vitamin D supplementation, in osteopenic
Crohn’s disease patients improved bone density at
lumbar spine.
NTR 163 Dutch Trial Register.
INTRODUCTION
Crohn’s disease (CD) is associated with a decreased
bone mineral density (BMD) and causes bone loss,
Significance of this study
What is already known on this subject?
▸ Bone loss is a feature of Crohn’s disease,
leading to osteoporosis and bone fractures,
occurring also at a relatively young age.
▸ Treatment of Crohn’s disease-associated bone
loss is primarily based on findings in senile
osteoporosis.
▸ Bisphosphonates are beneficial in treating
(senile) osteoporosis.
What are new findings?
▸ Early treatment of osteopenia in Crohn’s
disease patients improves bone density.
▸ Medical treatment with 35 mg risedronate
orally, once weekly, has a more beneficial
effect on bone density in osteopenic Crohn’s
disease patients than supplementation of
calcium and vitamin D alone.
▸ Treatment effects of risedronate were mainly
observed in the first 12 months of treatment in
this 24-month randomised trial.
How might it impact on clinical practice in
the foreseeable future?
▸ Early treatment of decreased bone mineral
density (thus, osteopenia) in relatively young
Crohn’s disease patients by risedronate once
weekly improves bone density, which may
decrease the incidence of
osteoporosis-associated bone fractures
occurring at a more mature age, a hypothesis
to be substantiated by formal study.
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osteoporosis and fractures.1–4 In CD, the prevalence of osteope-
nia (−2.5 <T-score <−1) has been reported to be as high as
50% in specific subpopulations, and osteoporosis (T-score
≤−2.5) is encountered in up to 30% of patients.5 A number of
longitudinal studies concerning BMD in IBD patients have con-
firmed these results; however, a significant heterogeneity in the
rate of bone loss has been observed. Overall, incidence and
prevalence of low bone mass are high in IBD, as has been docu-
mented in the Netherlands as well.6 Importantly, this bone loss
is associated with an increased fracture rate in IBD patients,
necessitating preventative therapeutic strategies.1 3 7–9
Risk factors for decreased bone mass in general comprise
genetic factors leading to low peak bone mass, low body mass
index (BMI), hypogonadism, other hormonal factors, immobility
and smoking habits. In IBD, additional factors are considered to
contribute to excessive bone loss including malabsorption and
vitamin D deficiency, (terminal) ileum resection, disturbances of
calcium homeostasis, drug use, in particular glucocorticoids, but
most of all, ongoing chronic (intestinal) inflammation.4 10–12
The pathogenesis of bone loss and subsequent osteoporosis in
patients with CD is complex and differs from decreased bone
mass as a result of the ageing process.4 5 10 This has recently
been underlined by description of the histomorphometric char-
acteristics of patients with quiescent CD in which reduction in
bone mass due to trabecular thinning and reduced bone forma-
tion (as a consequence of reduced osteocyte viability) were spe-
cific for CD-associated bone loss.13
Early interventions to treat active CD and preventative treat-
ment strategies to reduce excessive bone loss might prevent long
term consequences of bone loss, including fractures.
Risedronate, a bisphosphonate, improves bone quantity and
quality in osteoporosis. To date, risedronate is globally approved
in the treatment of postmenopausal osteoporosis to reduce the
risk of fractures and in osteoporosis in men at high risk of frac-
tures. We conducted a double-blind, randomised trial to assess
the effects of early therapeutic intervention to protect bone
mass by means of early treatment with risedronate in CD




A multicentre, prospective, double-blind, placebo-controlled
trial was conducted in eight large IBD referral centres in The
Netherlands. Eligible patients were recruited from these hospi-
tals comprising of seven out of the eight Dutch academic
medical centres, joined together in a national consortium for
IBD research, the Initiative on Crohn and Colitis, and one
large regional referral hospital (Medical Spectrum Twente,
Enschede).
Patients provided written informed consent before any study
procedure was conducted. They were included if they had estab-
lished quiescent CD by standard clinical, histological, and endo-
scopic criteria and osteopenia. Osteopenia was defined as per
usual WHO criteria, that is, a T-score value between −1.0 and
−2.5 as assessed by standard dual x-ray absorptiometry (DXA)
from lumbar spine or total hip.14 Disease activity was assessed by
Crohn’s Disease Activity Index (CDAI) and C reactive protein
(CRP) concentration. A CDAI <220 and CRP <10 mg/L were
considered to represent quiescent CD.
Patients were between 18 and 70 years of age. No gluco-
corticoid therapy (more than 7.5 mg prednisolone-equivalent
daily) was allowed in the 3 months prior to screening or during
the screening phase, and use of bisphosphonates was disallowed
for 12 months prior to study. In addition, patients with malab-
sorptive syndromes and patients with documented diseases with
an impact on bone metabolism or medication specifically aimed
to improve bone metabolism were excluded. Vitamin D defi-
ciency was an exclusion criterion and therefore serum
25-hydroxyvitamin D concentration had to be above 25 nmol/L.
Pregnancy or wish to become pregnant was an exclusion
criterion.
Disease and patient characteristics to be recorded comprised
sex, age, BMI, years after diagnosis of CD, localisation of CD,
(immunosuppressive) medication use and surgical history with
respect to CD.
Study variables included BMD, bone serum markers and
radiographs of the spine.
Bone mineral density
Bone density was assessed by means of standard DXA by a
Hologic device (models Delphi A, Discovery A, Discovery Ci, and
QDR 4500A; Hologic Benelux BV, Almere, The Netherlands) in
all centres but one in which another device was used (Lunar
Prodigy, General Electric Healthcare Company, The
Netherlands);14 15 device-specific reference values (including cor-
responding T-scores) were used. All centres performed daily cali-
bration according to local protocol and manufacturer’s
instruction. At the end of the study, a phantom measurement
(European Spine Phantom, QRM-ES, Möhrendorf, Germany) was
performed in all centres to allow for statistical analysis with adjust-
ment for inter-centre differences in measurement of outcome.
BMD was measured at lumbar spine (L1–4) and at the hip of the
non-dominant side. At baseline, duplicate measurements were per-
formed from which the mean was considered to be the correct
value. BMD was expressed as T-score and in g/cm2.
Serum bone turnover markers
Specific serum bone turnover markers comprised the bone for-
mation marker N-terminal propeptide of procollagen type 1
(P1NP; radioimmunoassay, Orion Diagnostica, Espoo, Finland)
and the bone resorption marker C-terminal cross-linked telo-
peptide of collagen type 1 (CTx; immunoassay, Roche
Diagnostics, Basel, Switzerland). The intra-assay and inter-assay
coefficient of variation of the P1NP assay were 4% and 8%,
respectively, and of the CTx assay 1.7% and 4.7%, respectively.
Radiographs of spine
Standardised anterior–posterior and lateral radiographs of thor-
acic and lumbar spine were obtained. All radiographs were semi-
quantitatively and centrally scored for the presence of vertebral
fractures by three dedicated investigators (VKD, AEO, PL).
When height loss of the vertebral body was 20% or more
anteriorly, in the middle or posteriorly, it was considered a ver-
tebral fracture. A height loss of 20%–25% was scored ‘mild’
(grade 1), 25%–40% was scored ‘moderate’ (grade 2) and a
height loss of >40% was scored ‘severe’ (grade 3).
Study design and follow-up
At screening, medical history, physical examination, CD activity
scores (CDAI and CRP), DXA in duplo, standard haemato-
logical and biochemical parameters and a pregnancy test, if
applicable, were obtained. At baseline, disease activity and con-
comitant medication were documented again and serum
markers for bone metabolism were drawn. Spine radiographs
were performed.
Patients had a follow-up visit at month 3, 6, 12, 18 and 24,
during which medical history, disease activity, concomitant
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medication (including drugs necessary for the treatment of
(flares of) CD, as per physician’s discretion), adverse events,
standard safety laboratory measurements and markers of bone
metabolism were collected. DXA was performed at 12 and
24 months of follow-up. Spine radiographs were made again
after 24 months.
Randomisation and treatment
According to study design, treatment with risedronate or
placebo was started after baseline measurements in patients who
met all inclusion criteria. The digital randomisation procedure
was performed by the central pharmacist (P Bet, VU University
medical centre, Amsterdam). Study treatment was dispensed in
lots of four blinded drug packages per hospital. Patients received
either 35 mg risedronate (Actonel) once per week or placebo
once per week. Both groups received a supplement containing
calcium and vitamin D (1000 mg and 800 IU, respectively,
Calci-Chew D3) daily at night-time and not together with the
study drug. In case of intolerance for Calci-Chew D3, substi-
tutes containing 1000 mg calcium and 400–800 IU vitamin D
were prescribed. Treatment was continued for 24 months.
Outcome variables
The primary outcome of the study was the change in BMD and
T-score at lumbar spine and/or total hip derived from DXA after
24 months treatment with risedronate compared with placebo.
Additionally, changes in markers of bone metabolism and
number of vertebral fractures were documented. CD activity
and safety of drug administration were monitored by clinical
scores (CDAI, CRP) and routine clinical, haematological and
biochemical parameters.
Study conduct
The study was performed according to the guidelines of Good
Clinical Practice and monitored by an external, non-participating,
research organisation (Denys Research Consultants, Wetteren,
Belgium). The study was centrally approved by the Medical
Ethical Committee of the Academic Medical Centre, Amsterdam
(subsequently followed by approval of all local MECs) and regis-
tered as NTR 163 Dutch Trial Register.
Sample size calculation
Assuming an SD in T-score at lumbar spine or total hip of
4.7%, 57 patients in each group would allow detection of a stat-
istically significant difference between the two treatments of
2.5% in lumbar spine or total hip T-score, with a type I error of
5% (2-sided) and a type II error of 20% (power 80%).
Including approximately a 10% drop out, 65 patients per study
arm were anticipated to be needed.
Statistical analysis and preparation of article
Analysis of the primary outcome was performed on all patients
who were allocated for drug use, defined as the intention to
treat population. In case of missing DXA measurement at
24 months, baseline DXA scores were imputed, being the most
stringent imputation method. The safety population was defined
as all subjects exposed to study treatment, regardless of the
amount of treatment administered. In the event of subjects
having received treatments that differed from those assigned
according to the randomisation schedule, then the safety ana-
lyses were conducted according to the treatment received rather
than according to the randomisation groups.
Box and Whisker plots were used to assess normality of all
outcome variables at baseline, and at months 3, 6, 12, 18 and 24.
Comparisons between the two groups with regard to the study out-
comes were performed by the two sample independent t test
(normal outcomes) or Mann–Whitney test (skewed outcomes) in
case of continuous outcomes and by the χ2 test in case of categorical
outcomes. Longitudinal measurements of DXAvalues, CDAI scores,
CRP values and serum values between the two groups were analysed
by a mixed model with fixed effects for group, time and their
two-way interaction and a random intercept for subjects. The ana-
lysis of DXA measurements was adjusted for age (fixed effect), BMI
(fixed effect), sex (fixed effect) and study centre (random effect).
Only patients with complete measurements were analysed; however,
in case of missing serum values at month 12, the measurement at
month 6 was put forward, as was done with lacking values at month
24, in which case observations of month 18 were put forward.
Statistical analyses were performed using SPSS (V.20, IBM
Corp., Armonk, New York, USA). A p value <0.05 was consid-
ered to indicate statistical significance, and a p value <0.1 a stat-
istical trend.
RESULTS
A total of 132 patients provided informed consent; as one
subject withdrew informed consent before randomisation, 131
patients were analysed. Of these 131, 67 received placebo and
64 risedronate (see figure 1).
Patient characteristics are depicted in table 1. There were no
clinically significant differences between the two treatment
groups, although the risedronate group had a slightly higher
BMI (24.3 vs 23.0 kg/m2). The main results of change in BMD
from baseline to month 24 are shown in table 2. The mean
BMD of lumbar spine of patients receiving risedronate increased
by 0.04 g/cm2, which was statistically significantly more than the
mean change of BMD in patients receiving placebo (p=0.007).
Also, the increase of the T-score of the lumbar spine was higher
in the risedronate than in the placebo group (p=0.007). The
increase of total hip BMD did not differ between the two
groups, although a statistical trend was observed for BMD in
favour of the treatment group.
These results were adjusted for age, sex, study centre and
BMI, and statistical findings remained consistent (see table 2);
likewise, no interaction between the main outcome and age
could be demonstrated (p=0.661 for lumbar T-score).
Standardised phantom measurements, performed following
inclusion of all patients according to protocol, ranged from
0.913 to 1.030. These inter-hospital differences were applied to
adjust and recalculate bone mass values which did not change
the conclusions of statistical analyses.
Complete DXA measurements were available for 118 patients
(see figure 1). A total of 14 patients were excluded from analysis
because of withdrawal of consent (n=6), non-compliance to
data acquirement according to the study protocol (n=5),
adverse reaction to immune suppressants (n=2) and vitamin D
deficiency (n=1). Per protocol analyses were done in the
remaining 118 patients. The median CDAI score was 88 (IQR
38.5–137.5) at baseline in the placebo group, and 75 (IQR
42.8–126.3) in the risedronate group. At month 24, this was 82
(IQR 34–127.5) in the placebo group versus 67 (IQR 34.0–
112.0) in the risedronate group. The median CRP value did not
change over time. For the placebo group, the median CRP was
3.0 mg/mL (IQR 1.4–7.0) at baseline and 3.0 mg/mL (IQR 2.0–
7.1) at the end of study, and in between ranged from 3.0 to
4.0 mg/mL. Median CRP values were 4.4 mg/mL (IQR 2.5–7.1)
and 4.5 (IQR 2.5–7.0) at baseline and at the end of study for
the risedronate group, and in between ranged from 4.0 to
5.0 mg/mL. All these values were consistent with CD in
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remission and differences between placebo and risedronate
groups were not significant. CDAI above 220 points or CRP
above 20 mg/mL, variables indicative of disease activity, were
observed at various evaluation time points, but in maximal five
subjects per group per evaluation moment, comprising finally
21 out of 118 patients of the total population, when taking all
study observations into account.
A total of 19 vertebral fractures were observed in 17 of the
131 participants at baseline, of which two fractures in two
patients were lost during follow-up. In the remaining completely
analysed 118 patients, 17 fractures in 15 patients at baseline
were mild, grade 1 fractures, in 11 patients in the thoracic and
in four patients in the lumbar spine. After 2 years follow-up,
one new grade 1 fracture was observed in a patient using
placebo. In three out of 118 patients, a grade 1 fracture
increased to a grade 2 fracture, all in the thoracic spine.







Age in years, mean (SD) 42 (13) 42 (13) 43 (13) 0.73
BMI, mean (SD) 23.6 (3.2) 23.0 (2.8) 24.3 (3.4) 0.02
Duration of CD, median
(IQR)
11 (6–18) 10 (6–17) 12 (6–21) 0.51
Sex
Male 60 (46%) 29 (43%) 31 (48%) 0.60
Female 71 (54%) 38 (57%) 33 (52%)
Localisation
Ileum (L1) 29 (22%) 17 (25%) 12 (19%) 0.63
Colon (L2) 31 (24%) 13 (19%) 18 (28%)
Ileocolonic (L3) 69 (53%) 36 (54%) 33 (52%)
Proximal (L4) 2 (2%) 1 (1%) 1 (2%)
Drugs
None 2 (2%) 1 (1%) 1 (2%) 0.71
Corticosteroids* 20 (15%) 8 (12%) 12 (19%)
Immunosuppressives 72 (55%) 32 (48%) 40 (63%)
Anti-TNF-α therapy 13 (22%) 7 (10%) 6 (9%)
Miscellaneous, IBD 92 (98%) 46 (69%) 46 (72%)
Non-IBD medication 86 (66%) 48 (72%) 38 (59%)
Medical
None 8 (6%) 5 (7%) 3 (5%) 0.43
History
IBD-related surgery 82 (63%) 40 (60%) 42 (66%)
IBD-associated
arthropathy
3 (2%) 0 (0%) 3 (5%)
Perianal disease
±local surgery
36 (27%) 18 (27%) 18 (28%)
Numbers expressed in n and %.
*At baseline, two patients used low dose prednisolone for CD, two for rheumatoid
arthritis and all others used budesonide. During the course of study, eight
prednisolone induction courses were initiated and tapered for CD exacerbation, four
patients received prednisolone for rheumatoid indications, and one patient each for
pulmonary disease, allergy, dermatological findings and multiple sclerosis,
respectively. Sixteen patients received anti-TNF-α therapy during study. All patients
were equally distributed over the two study groups (p=0.54).
BMI, body mass index; CD, Crohn’s disease.
Table 2 Change in DXA bone mineral density (BMD) and T-score









Baseline 0.95 (0.11) 0.94 (0.11)
24 months 0.96 (0.12) 0.98 (0.10) 0.007 0.013
T-score
Baseline −1.26 (0.78) −1.30 (0.61)
24 months −1.17 (0.94) −1.02 (0.75) 0.007 0.003
Z-score
Baseline −0.83 (0.81) −0.91 (0.68)
24 months −0.72 (0.95) −0.61 (0.79) 0.005 0.001
Total hip
BMD in g/cm2
Baseline 0.81 (0.11) 0.81 (0.09)
24 months 0.82 (0.08) 0.84 (0.11) 0.071 0.094
T-score
Baseline −1.21 (0.51) −1.22 (0.63)
24 months −1.16 (0.54) −1.07 (0.70) 0.192 0.228
Z-score
Baseline −0.80 (0.60) −0.83 (0.71)
24 months −0.74 (0.60) −0.67 (0.77) 0.091 0.110
Numbers expressed as mean and SD.
*p Value for the comparison of the change in DXA from baseline to 24 months
between the placebo and risedronate groups.
†p Value for the corrected model for age, sex, centre and BMI.
BMI, body mass index; DXA, dual x-ray absorptiometry; ITT, intention to treat.
Figure 1 Flowchart patients. Patients
with all dual x-ray absorptiometry
measurements were analysed in this
study (n=118).
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Distribution of prevalent fractures between the placebo and the
risedronate groups was similar (p=0.78 at baseline and p=1.00
after 24 months).
Serum bone formation and resorption markers (P1NP and
CTx, respectively) values were maximal at baseline, decreased in
the first 12 months of follow-up and slightly increased again
towards the end of the study after 24 months, for both variables
(figure 2). p Values are depicted in table 3.
No statistically significant association among serum markers
of bone metabolism, CDAI or CRP and bone density was
observed.
In total, 34 severe adverse advents (SAE) were observed in 24
patients, being surgical procedures (n=13, 10 CD-related),
gastroenteritis with or without dehydration (n=5), vascular
events (in four patients), carcinoma (in two patients) and miscel-
laneous (mainly hospital admissions for general reasons such as
exacerbation of dyspnoea, dehydration, allergic reaction,
retained video capsule and kidney stones). None of these SAEs
was considered to be associated with participation in this study
or use of the prescribed study medication. Relevant changes of
any laboratory value indicative for AE were not observed.
DISCUSSION
This double-blind, placebo-controlled study demonstrated an
increase of lumbar spine bone density in osteopenic patients
with quiescent CD while treated with the bisphosphonate rise-
dronate 35 mg once weekly with concomitantly calcium and
vitamin D; a statistical trend of bone density improvement was
seen at the total hip. One new grade 1 fracture was observed
during the study, and three existing grade 1 fractures aggravated
Figure 2 Mean values of lumbar dual x-ray absorptiometry in g/cm2 (A), serum concentration of bone resorption marker C-terminal cross-linked
telopeptide of collagen type, CTx, in ng/L (B), and of bone formation marker N-terminal propeptide of procollagen type 1, P1NP, in mg/L (C) at
baseline, after 12 and 24 months, with SEM between bars. The solid line represents the risedronate group, and the dashed line the placebo group.
Table 3 Change in serum bone turnover markers in all ITT
patients: the specific bone resorption marker C-terminal cross-linked
telopeptide of collagen type (CTx) and the bone formation marker
N-terminal propeptide of procollagen type 1 (P1NP)
Placebo, n=62 Risedronate, n=56 p Value*
CTx
Baseline 329.6 (166.0) 289.8 (170.7) NS
12 months 281.8 (139.1) 171.3 (149.0) 0.001
24 months 297.4 (142.1) 199.2 (156.4) 0.004
P1NP
Baseline 57.6 (22.1) 51.6 (38.4) NS
12 months 45.1 (14.9) 28.9 (19.1) <0.001
24 months 49.7 (18.9) 33.9 (19.6) <0.001
Numbers expressed as mean and SD.
*p Value for the comparison of the CTx or P1NP values between the placebo and
risedronate groups at 12 or 24 months.
ITT, intention to treat.
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to a grade 2 fracture, but the study was not statistically powered
to detect differences in fracture rate between placebo and rise-
dronate use.
Risedronate treatment was well tolerated, not influencing
disease activity, and its use was not associated with severe
adverse events.
The beneficial therapeutic effect of risedronate was substan-
tiated by a decrease in bone turnover markers, that is, the bone
formation marker P1NP and the bone resorption marker CTx,
consistent with the known pharmacological effects of bispho-
sphonates.16 The established pharmacodynamic effects in this
population showed that risedronate had adequate bioavailability
in terms of obtained pharmacological efficacy, even in CD
patients.
Peak bone mass may be reduced in CD (occurring at young age),
whereas increased bone loss is to be anticipated during periods of
chronic active or relapsing disease. This contributes to an increased
risk of osteopenic or osteoporotic bone, usually at a younger age,
and may partly explain the reported increase in fractures in IBD
patients.4 10 Several studies have shown that bisphosphonates, pri-
marily by intravenous administration, are effective in the treatment
of bone loss of CD patients, although not all were performed in a
randomised, placebo-controlled and double-blind fashion.17–23
Study populations differed substantially in age, sex, disease activity,
and therapeutic effects on trabecular or cortical bone. In a number
of studies, evaluating the effect of oral administration of bispho-
sphonates on BMD in various small cohorts of IBD patients, com-
parable results were observed.24–28 Analogous findings in a similarly
designed study were reported by Soo et al,28 but the outcome was
not statistically significant, probably due to the small number of
included patients. Notably, the decrease of bone turnover markers,
which can be ascribed to the pharmacodynamic effect of risedro-
nate, and an effect which may be primarily observed in the first
period of treatment, underscores the role of bisphosphonates and
not of the dietary calcium and vitamin D supplements in our
study.29 Increase of BMD was yet shown when only calcium and
vitamin D were supplemented in a selected cohort of CD patients
with a low bone mass from one of the participating study centres.30
This was, however, a minor increase over years (0.43% and 0.76%
in total hip and lumbar spine, respectively), and less than the
reported effects of risedronate use in the current study.30 This also
holds true for the potential beneficial effect of anti-TNF-α therapy
on bone density, an effect that is known to induce different changes
of serum bone markers.31 In this study, patients using or initiating
anti-TNF-α therapy were equally distributed between the risedro-
nate and the placebo groups (table 1).
In a subpopulation of this study, bone biopsies were obtained
to analyse specific characteristics of CD-induced changes in
bone architecture. These comprised reduction in bone mass due
to trabecular thinning and reduced bone formation.13
Subsequent experiments showed that bone cells from patients
with CD had a reduced growth potential and an impeded mat-
uration, and increased potential to generate osteoclasts from
peripheral blood.32 33 These mechanisms probably contribute to
the pathogenesis of CD-induced bone loss and differ from
osteoporosis due to ageing. Nevertheless, bisphosphonates, a
well-established therapy for age-induced osteoporosis in
women, proved to successfully increase bone density in
CD-associated osteopenia.17–23
In this trial, in a well-documented, osteopenic CD population,
the beneficial effect of therapy was shown in particular at the
lumbar spine, whereas the total hip findings showed a statistical
trend of improvement, probably because lumbar spine changes
due to medical treatment may be detected earlier and more
reliably.34 Additionally, concurrent with the improvement of
BMD, we showed a change in pharmacodynamic variables con-
sistent with the specific effects of bisphosphonates (decrease of
serum bone turnover markers P1NP and CTx), excluding con-
founding effects of calcium and vitamin D supplementation or
treatment of CD, for example, by means of infliximab. The
results of this study corroborate the concept that early bone pro-
tective treatment in osteopenic CD patients may prevent frac-
tures and associated complications at later age.3 10 Considering
the established increased risk of fractures in CD patients, the
current study results support more frequent and early use of
risedronate in CD patients with an increased risk of metabolic
bone disease and fractures, in this study identified as CD
patients having osteopenia. As such, this preventive strategy may
be recommended in particular risk groups, such as CD patients
suffering from chronic active disease, those with chronic or high
cumulative dose of glucocorticoids, a family history of osteopor-
otic fractures, and those with a low BMI.
This double-blind study showed a beneficial effect of risedro-
nate in osteopenic CD patients as assessed by DXA. Quality of
bone, assessed by bone histomorphometry, could only be
assessed in a relatively small subgroup.13 We did not measure
risedronate concentrations in serum to ascertain treatment com-
pliance, but calculated the number of tablets returned to the
investigators at follow-up visits. This holds true for calcium and
vitamin D supplements as well, although, due to randomisation,
no skewing in compliance between the two groups was to be
expected. The positive effect of risedronate on BMD provides
additional proof for adequate intake and absorption of this
bisphosphonate in our patients with IBD.
In conclusion, we demonstrated that risedronate 35 mg once
weekly with concomitant calcium and vitamin D supplementa-
tion improved BMD in an osteopenic CD population.
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